To view or add a comment, sign in --$. - Novo Nordisk is aggressively building its rare disease arsenal beyond diabetes and obesity: They gain exclusive global rights to zaltenibart (formerly OMS906, an investigational MASP-3 inhibitor for complement-mediated blood and kidney disorders), which was in Phase 3 preparation for paroxysmal nocturnal hemoglobinuria (PNH) before Omeros paused the program due to capital constraints
The switch comes because, according to them, there are now more alternative weight-management options out there
Agarwal A, Gupta S, Sikka S
Moloi, M
The observed effects included increased tanning, supporting the effectiveness of MT-II as a sunless tanning agent, administered at low doses every other day [5]
In my opinion, the brand Ishigaki is one of the cheapest brands of glutathione in the market today